Keyword search (3,448 papers available)


Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.

Author(s): Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestik...

J Psychiatry Neurosci. 2020 Jun 19;45(4):190162 Authors: Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mesti...

Article GUID: 32559027
mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use.

Author(s): Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl R...

Neuropsychopharmacology. 2020 May 15;: Authors: Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, C...

Article GUID: 32413893
Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans.

Author(s): Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1175-1178 Authors: Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M

Article GUID: 30607444
Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors.

Author(s): Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1179-1183 Authors: Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M

Article GUID: 30627817
Title:Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.
Authors:Smart K,  Nagano-Saito A,  Milella MS,  Sakae DY,  Favier M,  Vigneault E,  Louie L,  Hamilton A,  Ferguson SSG,  Rosa-Neto P,  Narayanan S,  El Mestikawy S,  Leyton M,  Benkelfat C
Link:https://www.ncbi.nlm.nih.gov/pubmed/32559027?dopt=Abstract
DOI:10.1503/jpn.190162
Category:J Psychiatry Neurosci
PMID:32559027
Dept Affiliation: CSBN
1 From the Department of Psychiatry, McGill University, Montreal, Que. (Smart, Nagano-Saito, Milella, Sakae, Favier, Vigneault, Louie, Rosa-Neto, El Mestikawy, Leyton, Benkelfat); the Douglas Mental Health University Institute, McGill University, Montreal, Que. (Smart, Sakae, Favier, Vigneault, Rosa-Neto, El Mestikawy); the Department of Cellular and Molecular Medicine, University of Ottawa, Ont. (Hamilton, Ferguson); the McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Que. (Rosa-Neto, Narayanan, Leyton, Benkelfat); the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Que. (Rosa-Neto, Narayanan, Leyton, Benkelfat); and the Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Que. (Leyton).

Description:

Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.

J Psychiatry Neurosci. 2020 Jun 19;45(4):190162

Authors: Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C

Abstract

Background: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood.

Methods: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [3H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [11C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence.

Results: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neur.

Limitations: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences.

Conclusion: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization.

PMID: 32559027 [PubMed - as supplied by publisher]